# Compugen Ltd. (CGEN)

> Source: Nexqual · https://nexqual.com/CGEN · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Compugen Ltd. (CGEN), nexqual.com/CGEN" · informational, not investment advice.

**Price:** USD 1.96 (-7.55% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 2.12 · day 1.92–2.14 · 52w 1.43–3.24 · market cap $186M · NCM

## Key facts
- 1 of 80 tracked superinvestors hold CGEN (13F, Q3 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 7 Form 4 filings, $74K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 4.6 (range 4–6).
- Total return with dividends: 1Y +17.4% vs S&P 500 +14.9%; 5Y -68.1% vs S&P 500 +80.3%.
- Next earnings: 2026-11-09, EPS estimate USD -0.09, revenue estimate $975K.

## Superinvestors (SEC 13F-HR, Q3 2026)
1 of 80 tracked investors hold CGEN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| David Katz | Matrix Asset Advisors | 0.02% | $223K | Unchanged |

## Insider sales (SEC Form 4, open-market, last ~7 months)
7 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-07-09 | Levine Zurit | SVP, Business Development | 1,875 | $5K | 6% | Yes (adopted December 23, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-04-24 | Levine Zurit | SVP, Business Development | 2,000 | $6K | 6.4% | Yes (adopted December 23, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-04-24 | Ophir Eran | President and CEO | 5,000 | $16K | 30.5% | Yes (adopted December 26, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-04-14 | Ophir Eran | President and CEO | 5,000 | $15K | 30.5% | Yes (adopted December 26, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-04-14 | Levine Zurit | SVP, Business Development | 2,000 | $6K | 6.4% | Yes (adopted December 23, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-04-10 | Levine Zurit | SVP, Business Development | 3,125 | $8K | 9.6% | Yes (adopted December 23, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-04-07…2026-04-08 | Levine Zurit | SVP, Business Development | 7,875 | $19K | 21.1% | Yes (adopted December 23, 2025) | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 4.6 (low 4, high 6).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | HC Wainwright & Co. | Reiterated | Buy | $4 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +17.4% | -68.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +17.4% | -20.4% |
| Volatility (annualized) | 63.8% | 78.8% |
| Max drawdown | -36.8% (Apr 2026→Jun 2026) | -91.4% (Nov 2021→Oct 2022) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/CGEN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in CGEN's own 20-F filed 2026-03-02 (https://www.sec.gov/Archives/edgar/data/1119774/000117891326000663/zk2634416.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | ASTRAZENECA PLC (AZN) | "We currently have two therapeutic program-based partnership agreements in effect, one with AstraZeneca plc, or AstraZeneca, and the second" |
| Partner | MedImmune | "with an amendment to our previously existing exclusive license agreement with MedImmune Limited, the global biologics research and development" |
| Partner | Pfizer (PFE) | "Notably, recent years saw multiple high-profile alliances, for instance, Pfizer's $1.25 billion licensing of a cancer antibody" |
| Partner | Leerink Partners | "finance our needs through the issuance of equity securities, including through our Sales Agreement with Leerink, debt securities or other" |
| Partner | Johnson & Johnson (JNJ) | "Ltd., an Israeli biotechnology accelerator established by OrbiMed Israel Partners, Johnson & Johnson Innovation, Takeda Ventures Inc.," |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.09 | $-0.09 | +2.0% | $975,000 | 3 |
| Next quarter (ends 2026-12-31) | $-0.09 | $-0.09 | +2.0% | $3.5M | 3 |
| Current fiscal year (ends 2026-12-31) | $-0.33 | $-0.34 | -2.9% | $9.2M | 3 |
| Next fiscal year (ends 2027-12-31) | $-0.37 | $-0.36 | +0.5% | $7.8M | 3 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-12-18 (includes earnings 2026-11-09): ±27.6%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-12-18 | 56 | 71.7% | ±27.6% |
| 2027-03-19 | 147 | 86.8% | ±52.8% |